Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

FDA advise rosiglitazone reviews

The Food and Drugs Administration in America has issued a safety alert for rosiglitazone in response to cardiovascular safety concerns raised by the New England Journal of Medicine (NEJM).

As previously discussed, the meta-analysis in the NEJM revealed a statistically significant 43% increase in myocardial infarctions and a non-significant 64% increase in the risk of cardiovascular death in patients taking rosiglitazone when compared to controls (placebo or other hypoglycaemics).

The FDA are advising that patients who have heart disease, or who are at high risk of developing heart disease, should talk to their doctor about this new information and the treatment options.

Action: Clinicians should be aware of this evolving situation and be prepared to discuss the risks and benefits of the alternative treatment options with concerned patients.

Share 'FDA advise rosiglitazone reviews' on Email Share 'FDA advise rosiglitazone reviews' on Delicious Share 'FDA advise rosiglitazone reviews' on Digg Share 'FDA advise rosiglitazone reviews' on Facebook Share 'FDA advise rosiglitazone reviews' on Google+ Share 'FDA advise rosiglitazone reviews' on reddit Share 'FDA advise rosiglitazone reviews' on StumbleUpon Share 'FDA advise rosiglitazone reviews' on Twitter

atomic-wealth

No Comments to “FDA advise rosiglitazone reviews”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,657 spam comments.

atomic-wealth
fond-illness
summer